<a href="https://www.fiercebiotech.com/medtech/boston-scientific-funnels-15b-mirus-pens-option-buy-its-tavr-system" hreflang="en">Boston Scientific funnels $1.5B into MiRus, with option to buy TAVR system </a>
fiercebiotech.com·May 18, 2026
Boston Scientific is making a significant investment in a private medtech company, securing an option for exclusive rights to its Transcatheter Aortic Valve Replacement system.
Boston Scientific's strategic investment in a private medtech company with an option for exclusive rights to its Transcatheter Aortic Valve Replacement system signals a valuable opportunity in the medtech space. For someone tracking medtech and potential acquisitions, this suggests a growing focus on minimally invasive cardiac technologies and might indicate a promising area for future investments or partnerships.